1873 — VIVA Biotech Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapNeutral

Annual income statement for VIVA Biotech Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,104	2,380	2,156	1,987	1,729
Cost of Revenue
Gross Profit	651	816	738	687	656
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,711	2,664	2,209	1,637	1,369
Operating Profit	393	-285	-53.7	350	360
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	348	-459	-56	296	318
Provision for Income Taxes
Net Income After Taxes	301	-504	-99.8	222	269
Minority Interest
Net Income Before Extraordinary Items
Net Income	288	-528	-116	167	220
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	163	-528	-116	167	220
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.081	-0.259	0.017	0.067	0.104
Dividends per Share